 |
| |
| Nov-14-18 | Downgrade |
JP Morgan |
Overweight → Neutral |
|
|
| Nov-09-18 | Downgrade |
Guggenheim |
Buy → Neutral |
|
|
| Oct-10-18 | Initiated |
Guggenheim |
Buy |
|
|
| Jun-20-18 | Initiated |
BofA/Merrill |
Buy |
$24 |
|
| Nov-15-17 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
|
|
| Jun-22-17 | Resumed |
Jefferies |
Buy |
$17 |
|
| Nov-01-16 | Downgrade |
Wedbush |
Outperform → Neutral |
$30 → $4 |
|
| Oct-19-16 | Downgrade |
Piper Jaffray |
Overweight → Neutral |
|
|
| Dec-04-15 | Initiated |
Wells Fargo |
Outperform |
|
|
| Oct-23-15 | Resumed |
Jefferies |
Buy |
|
|
| May-03-13 | Initiated |
BioLogic Equity Research |
Sell |
|
|
| Feb-23-11 | Reiterated |
JMP Securities |
Mkt Outperform |
$9 → $12 |
|
| Jul-29-10 | Reiterated |
Wedbush |
Outperform |
$12 → $13 |
|
| Oct-19-09 | Initiated |
Brean Murray |
Sell |
$4 |
|
| Oct-07-09 | Reiterated |
Leerink Swann |
Outperform |
$9 → $11 |
|
| Aug-25-09 | Reiterated |
JMP Securities |
Mkt Outperform |
$13 → $15 |
|
| Apr-14-09 | Downgrade |
Cantor Fitzgerald |
Buy → Hold |
|
|
| Feb-23-09 | Reiterated |
Leerink Swann |
Outperform |
$6 → $9 |
|
| Feb-05-09 | Upgrade |
Merriman Curhan Ford |
Neutral → Buy |
|
|
| Nov-20-08 | Reiterated |
Cantor Fitzgerald |
Buy |
$27 → $4 |
|
|
|
| Feb-14-19 12:01PM | Is Moderna a Buy? Motley Fool |
| Feb-12-19 08:30AM | Biotech Stocks Rising ACCESSWIRE +7.57% |
| Feb-09-19 10:03AM | Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool |
| 08:16AM | Is Sangamo's Gene-Editing Approach a Bust? Motley Fool |
| Feb-08-19 09:17AM | The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga -7.10% |
| Feb-07-19 05:44PM | Why this East Bay biotech company shed half its value American City Business Journals -30.87% |
| 04:00PM | Why Sangamo Therapeutics Crashed Today Motley Fool |
| 01:43PM | Sangamo Fails To Impress Investors With Genome Editing Studies Benzinga |
| 12:07PM | Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles Bloomberg |
| 12:06PM | Tests suggest scientists achieved 1st 'in body' gene editing Associated Press |
| 11:00AM | Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I PR Newswire |
| 11:00AM | Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913 PR Newswire |
| 08:08AM | The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga |
| Feb-01-19 08:30AM | Sangamo Therapeutics To Host Conference Call To Review Interim Results From Phase 1/2 CHAMPIONS And EMPOWERS Studies For MPS II And MPS I PR Newswire +6.76% |
| Jan-29-19 07:45AM | Investor Expectations to Drive Momentum within Dollar General, Zayo Group, Cabot Oil & Gas, Sangamo Therapeutics, BioTelemetry, and Dean Foods Discovering Underlying Factors of Influence GlobeNewswire |
| Jan-24-19 09:35AM | Is Sangamo Therapeutics, Inc.s (NASDAQ:SGMO) CEO Salary Justified? Simply Wall St. |
| Jan-22-19 04:05PM | Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development PR Newswire |
| Jan-18-19 02:10PM | Here's How I Would Handle Speculative Sangamo Therapeutics TheStreet.com |
| 07:43AM | Jim Cramer Advises His Viewers On Brink's, Medtronic And More Benzinga |
| Jan-17-19 06:48PM | Cramer's lightning round: 'I'm not endorsing' Fiat Chrysler's stock anymore CNBC |
| Jan-11-19 05:00AM | Top Picks 2019- Sangamo Therapeutics SGMO MoneyShow |
| Jan-08-19 09:15AM | Portfolios Making Up For Lost Time Zacks |
| Jan-04-19 08:00AM | Sangamo Therapeutics To Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +8.06% |
| 08:00AM | Sangamo Announces Upcoming Clinical Data Presentations At WORLDSymposium 2019 PR Newswire |
| Dec-28-18 10:29AM | Biotech markets could be very promising in 2019 Yahoo Finance Video |
| Dec-20-18 05:59PM | Gilead Partners with Scholar Rock for Fibrotic Disease Drugs Zacks |
| Dec-17-18 08:00AM | Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Of In Vivo Genome Editing Therapy For Hemophilia B PR Newswire |
| Dec-11-18 03:55PM | Gilead Sciences (GILD) Appoints Daniel O'Day as New CEO Zacks |
| Dec-05-18 04:23PM | Gilead's (GILD) Harvoni and Descovy Get Approval in China Zacks |
| Dec-04-18 03:58PM | Gilead (GILD) Announces Data on CAR T Therapy Candidate Zacks -7.90% |
| 09:23AM | Is Sangamo Therapeutics Inc (NASDAQ:SGMO) A Financially Sound Company? Simply Wall St. |
| Dec-03-18 07:00AM | Sangamo Announces Completion Of TxCell Acquisition PR Newswire |
| Dec-02-18 09:02AM | Better Buy: Editas Medicine vs. Sangamo Therapeutics Motley Fool |
| Nov-28-18 08:45AM | Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. Future Expectations, Projections Moving into 2018 GlobeNewswire |
| Nov-26-18 08:25AM | Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth Zacks |
| Nov-20-18 04:02PM | Gilead's Vemlidy Gets Approval in China for HBV Infection Zacks |
| Nov-18-18 04:51PM | Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc. Motley Fool |
| 10:31AM | Cutting-edge biotech Sangamo stock dives 12% after JPMorgan cites growing skepticism in downgrade MarketWatch |
| Nov-15-18 09:44AM | Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes Zacks +8.94% |
| Nov-14-18 05:54PM | Here's Why Sangamo Therapeutics Lost 12% Today Motley Fool -11.94% |
| 08:19AM | Sangamo stock drops after J.P. Morgan downgrade MarketWatch |
| Nov-10-18 07:16AM | Here's Why Sangamo Therapeutics Inc. Fell 25.3% in October Motley Fool |
| Nov-08-18 11:36PM | Edited Transcript of SGMO earnings conference call or presentation 8-Nov-18 10:00pm GMT Thomson Reuters StreetEvents |
| 05:55PM | Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates Zacks |
| 04:01PM | Sangamo Therapeutics Reports Third Quarter 2018 Financial Results PR Newswire |
| Nov-06-18 04:01PM | Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences PR Newswire |
| Nov-01-18 08:30AM | Sangamo Therapeutics Announces Third Quarter 2018 Conference Call and Webcast PR Newswire +10.18% |
| Oct-29-18 11:12AM | What's in Store for Sangamo (SGMO) This Earnings Season? Zacks |
| Oct-18-18 06:31AM | Is Sangamo Therapeutics Inc. a Buy? Motley Fool |
| Oct-17-18 08:45AM | Analysis: Positioning to Benefit within New York, KB Home, Sangamo Therapeutics, INTL FCStone, Maiden, and MobileIron Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Oct-01-18 08:00AM | Sangamo and TxCell announce the completion of the acquisition by Sangamo of majority of TxCell ordinary shares PR Newswire |
| Sep-25-18 10:06AM | Implied Volatility Surging for Sangamo Therapeutics (SGMO) Stock Options Zacks |
| Sep-24-18 04:15PM | Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences PR Newswire |
| Sep-14-18 01:05PM | Major Stem Cell Breakthroughs Giving Investors Big Opportunity ACCESSWIRE |
| Sep-13-18 11:12AM | Who Are The Major Shareholders Of Sangamo Therapeutics Inc (NASDAQ:SGMO)? Simply Wall St. |
| Sep-09-18 10:40AM | Sangamo Therapeutics stock drops 24% on results of cutting-edge gene-editing trial MarketWatch |
| Sep-08-18 08:30AM | Heres What Was Behind Sangamos Horrendous Week Motley Fool |
| Sep-06-18 05:00PM | Why Sangamo Therapeutics, Inc. Sank Again Today Motley Fool -10.31% |
| 03:25PM | Gilead, Galapagos Spondylitis Drug Meets Primary Endpoint Zacks |
| 12:31PM | Is This Gene-Editing Stock Doomed? Motley Fool |
| 09:15AM | Tough Day for Tech as NASDAQ Slips 1%+ Zacks |
| 08:48AM | Sangamo's Zinc Fingers Fail Again. Time to Walk Away? Motley Fool |
| 08:00AM | Todays Research Reports on Stocks to Watch: ProQR Therapeutics and Sangamo Therapeutics ACCESSWIRE |
| Sep-05-18 05:04PM | What Happened in the Stock Market Today Motley Fool -23.62% |
| 03:27PM | Why Sangamo Therapeutics Stock Is Tanking Today Motley Fool |
| Sep-03-18 01:23PM | Why Sangamo Therapeutics Shot 33.7% Higher in August Motley Fool |
| Sep-02-18 09:41AM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings Benzinga |
| 09:33AM | 3 Biotech Stocks That Could Soar in September Motley Fool |
| Aug-31-18 08:51AM | Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 8% in Session Zacks |
| 08:00AM | Today's Research Reports on Trending Tickers: Sangamo Therapeutics and MEI Pharma ACCESSWIRE |
| Aug-30-18 01:38PM | A Lesson to Learn From Thursday's Market Action TheStreet.com +8.04% |
| 08:00AM | Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences PR Newswire |
| Aug-23-18 08:48AM | Is the Options Market Predicting a Spike in Sangamo Therapeutics (SGMO) Stock? Zacks |
| 08:10AM | Factors of Influence in 2018, Key Indicators and Opportunity within Aurora Cannabis, Canopy Growth, MobileIron, Sangamo Therapeutics, BioDelivery Sciences International, and First Solar New Research Emphasizes Economic Growth GlobeNewswire |
| Aug-21-18 11:45PM | Edited Transcript of SGMO earnings conference call or presentation 8-Aug-18 9:00pm GMT Thomson Reuters StreetEvents |
| Aug-15-18 06:00AM | What's Next for Spark Therapeutics Motley Fool -5.54% |
| Aug-13-18 08:17AM | 3 Biotech Stocks With Major Catalysts Incoming Motley Fool |
| Aug-10-18 08:00AM | Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference PR Newswire |
| Aug-09-18 12:20PM | Why Sangamo Therapeutics, Inc. Stock Is Popping Today Motley Fool +10.87% |
| 08:39AM | The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings Benzinga |
| 08:00AM | Today's Research Reports on Trending Tickers: Nektar Therapeutics and Sangamo Therapeutics ACCESSWIRE |
| Aug-08-18 05:40PM | Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 04:01PM | Sangamo Therapeutics Reports Second Quarter 2018 Financial Results PR Newswire |
| 04:01PM | Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A PR Newswire |
| 03:10PM | Backed with $140M, startup launches three-pronged attack on liver diseases American City Business Journals |
| 03:00PM | Sangamo Therapeutics, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-02-18 08:00AM | Sangamo Therapeutics Announces Second Quarter 2018 Conference Call and Webcast PR Newswire |
| Jul-31-18 04:01PM | Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913, An Investigational Genome Editing Treatment For MPS II, To Be Presented September 5th At SSIEM 2018 Symposium PR Newswire |
| Jul-27-18 08:30AM | Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D. PR Newswire |
| Jul-23-18 11:35AM | Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318 Benzinga |
| 08:37AM | Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock Zacks |
| 02:30AM | Sangamo Therapeutics to Acquire TxCell PR Newswire |
| Jul-13-18 04:15PM | Sangamo Therapeutics Announces Technology Leadership Changes PR Newswire |
| Jul-12-18 10:30AM | Stem Cell Companies Innovating For The Future ACCESSWIRE |
| Jul-08-18 03:15PM | Why bluebird bio's Shares Have Tumbled 11.9% in 2018 So Far Motley Fool |
| Jul-06-18 07:45AM | Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks ACCESSWIRE |
| Jun-29-18 08:10AM | Today's Research Reports on Trending Tickers: Endo International and Sangamo Therapeutics ACCESSWIRE |
| Jun-28-18 04:05PM | Sangamo Therapeutics Appoints Karen Smith to its Board of Directors PR Newswire |
| Jun-27-18 06:11PM | Why Sangamo Therapeutics and bluebird bio Slipped Lower Today Motley Fool -10.54% |
| Jun-20-18 02:09PM | Traders Are Still Finding Plenty of Stocks That They Want to Buy TheStreet.com +9.73% |
|
|
|
|
| Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Yi Kathy | SVP & Chief Financial Officer | Jan 15 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Jan 16 04:08 PM | | Yi Kathy | SVP & Chief Financial Officer | Jan 15 | Sale | 11.04 | 5,000 | 55,200 | 7,250 | Jan 16 04:08 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Jan 07 | Option Exercise | 3.20 | 5,000 | 16,000 | 17,125 | Jan 08 05:38 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Jan 07 | Sale | 12.33 | 5,000 | 61,631 | 12,125 | Jan 08 05:38 PM | | Yi Kathy | SVP & Chief Financial Officer | Dec 17 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Dec 18 05:35 PM | | Yi Kathy | SVP & Chief Financial Officer | Dec 17 | Sale | 11.44 | 5,000 | 57,200 | 7,250 | Dec 18 05:35 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Dec 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 17,125 | Dec 07 07:46 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Dec 06 | Sale | 11.49 | 5,000 | 57,433 | 12,125 | Dec 07 07:46 PM | | Yi Kathy | SVP & Chief Financial Officer | Nov 15 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Nov 16 05:16 PM | | Yi Kathy | SVP & Chief Financial Officer | Nov 15 | Sale | 10.00 | 5,000 | 50,000 | 7,250 | Nov 16 05:16 PM | | PARKER H STEWART | Director | Nov 14 | Buy | 9.00 | 2,000 | 18,002 | 7,500 | Nov 15 07:08 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Nov 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 17,125 | Nov 07 05:41 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Nov 06 | Sale | 13.73 | 5,000 | 68,650 | 12,125 | Nov 07 05:41 PM | | Yi Kathy | SVP & Chief Financial Officer | Oct 15 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Oct 16 07:25 PM | | Yi Kathy | SVP & Chief Financial Officer | Oct 15 | Sale | 13.97 | 5,000 | 69,850 | 7,250 | Oct 16 07:25 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Oct 08 | Option Exercise | 3.20 | 5,000 | 16,000 | 15,125 | Oct 09 05:40 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Oct 08 | Sale | 14.55 | 5,000 | 72,774 | 10,125 | Oct 09 05:40 PM | | Yi Kathy | SVP & Chief Financial Officer | Sep 17 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Sep 18 05:06 PM | | Yi Kathy | SVP & Chief Financial Officer | Sep 17 | Sale | 14.66 | 5,000 | 73,285 | 7,250 | Sep 18 05:06 PM | | PARKER H STEWART | Director | Sep 07 | Buy | 13.52 | 2,000 | 27,040 | 5,500 | Sep 07 05:45 PM | | JEFFS ROGER | Director | Sep 07 | Buy | 13.56 | 7,408 | 100,487 | 9,908 | Sep 07 07:18 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Sep 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 15,125 | Sep 07 04:39 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Sep 06 | Sale | 14.17 | 5,000 | 70,845 | 10,125 | Sep 07 04:39 PM | | Yi Kathy | SVP & Chief Financial Officer | Aug 16 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Aug 17 04:17 PM | | Yi Kathy | SVP & Chief Financial Officer | Aug 16 | Sale | 15.39 | 5,000 | 76,952 | 7,250 | Aug 17 04:17 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Aug 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 15,125 | Aug 07 07:28 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Aug 06 | Sale | 13.45 | 5,000 | 67,250 | 10,125 | Aug 07 07:28 PM | | Yi Kathy | SVP & Chief Financial Officer | Jul 16 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Jul 17 04:16 PM | | Yi Kathy | SVP & Chief Financial Officer | Jul 16 | Sale | 14.77 | 5,000 | 73,860 | 7,250 | Jul 17 04:16 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Jul 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 15,125 | Jul 09 06:58 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Jul 06 | Sale | 15.80 | 5,000 | 78,975 | 10,125 | Jul 09 06:58 PM | | Yi Kathy | SVP & Chief Financial Officer | Jun 15 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Jun 15 07:43 PM | | Yi Kathy | SVP & Chief Financial Officer | Jun 15 | Sale | 15.67 | 5,000 | 78,365 | 7,250 | Jun 15 07:43 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Jun 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 15,125 | Jun 07 04:06 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Jun 06 | Sale | 16.67 | 5,000 | 83,350 | 10,125 | Jun 07 04:06 PM | | Yi Kathy | SVP & Chief Financial Officer | May 15 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | May 16 06:38 PM | | Yi Kathy | SVP & Chief Financial Officer | May 15 | Sale | 15.38 | 5,000 | 76,920 | 7,250 | May 16 06:38 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | May 07 | Option Exercise | 3.20 | 5,000 | 16,000 | 15,125 | May 09 05:38 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | May 07 | Sale | 16.36 | 5,000 | 81,814 | 10,125 | May 09 05:38 PM | | Yi Kathy | SVP & Chief Financial Officer | Apr 16 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Apr 18 04:04 PM | | Yi Kathy | SVP & Chief Financial Officer | Apr 16 | Sale | 19.83 | 5,000 | 99,144 | 7,250 | Apr 18 04:04 PM | | Herberts Curt A. III | Sr.VP & Chief Business Officer | Apr 13 | Option Exercise | 14.07 | 8,163 | 114,853 | 22,788 | Apr 17 04:16 PM | | Herberts Curt A. III | Sr.VP & Chief Business Officer | Apr 13 | Sale | 20.00 | 8,163 | 163,260 | 14,625 | Apr 17 04:16 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Apr 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 13,125 | Apr 09 06:43 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Apr 06 | Sale | 17.41 | 5,000 | 87,065 | 8,125 | Apr 09 06:43 PM | | Mento Steven J | Director | Apr 02 | Option Exercise | 7.77 | 10,000 | 77,700 | 19,047 | Apr 04 04:10 PM | | Herberts Curt A. III | Sr.VP & Chief Business Officer | Apr 02 | Option Exercise | 5.35 | 2,278 | 12,199 | 16,903 | Apr 04 04:09 PM | | Herberts Curt A. III | Sr.VP & Chief Business Officer | Apr 02 | Sale | 18.30 | 2,278 | 41,684 | 14,625 | Apr 04 04:09 PM | | Mento Steven J | Director | Apr 02 | Sale | 18.40 | 7,215 | 132,758 | 11,832 | Apr 04 04:10 PM | | Yi Kathy | SVP & Chief Financial Officer | Mar 15 | Option Exercise | 4.55 | 5,000 | 22,750 | 12,250 | Mar 16 07:41 PM | | Yi Kathy | SVP & Chief Financial Officer | Mar 15 | Sale | 25.56 | 5,000 | 127,812 | 7,250 | Mar 16 07:41 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Mar 06 | Option Exercise | 3.20 | 5,000 | 16,000 | 13,125 | Mar 07 08:43 PM | | Conner Edward R. | Sr. VP & Chief Medical Officer | Mar 06 | Sale | 24.78 | 5,000 | 123,878 | 8,125 | Mar 07 08:43 PM | | Herberts Curt A. III | Sr.VP & Chief Business Officer | Mar 01 | Option Exercise | 9.86 | 15,000 | 147,905 | 29,625 | Mar 05 06:39 PM | | Mento Steven J | Director | Mar 01 | Option Exercise | 5.49 | 15,000 | 82,350 | 18,480 | Mar 05 06:50 PM | | Mento Steven J | Director | Mar 01 | Sale | 23.27 | 9,433 | 219,546 | 9,047 | Mar 05 06:50 PM | | Herberts Curt A. III | Sr.VP & Chief Business Officer | Mar 01 | Sale | 23.06 | 15,000 | 345,861 | 14,625 | Mar 05 06:39 PM | | Ramasastry Saira | Director | Feb 26 | Option Exercise | 5.03 | 9,450 | 47,534 | 9,450 | Feb 27 06:41 PM | | Ramasastry Saira | Director | Feb 26 | Sale | 24.88 | 9,450 | 235,080 | 0 | Feb 27 06:41 PM |
|
|
|
|
|
|
